Haemonetics (NYSE:HAE) Reaches New 52-Week High – Here’s Why

by · The Cerbat Gem

Haemonetics Corporation (NYSE:HAE – Get Free Report)’s share price reached a new 52-week high on Friday . The company traded as high as $85.23 and last traded at $84.81, with a volume of 82373 shares traded. The stock had previously closed at $83.81.

Analyst Ratings Changes

Several analysts have issued reports on HAE shares. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Raymond James Financial reissued an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. Barrington Research upped their price objective on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. BTIG Research reiterated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, November 21st. Finally, Citigroup lowered their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $79.70.

Check Out Our Latest Research Report on HAE

Haemonetics Stock Up 1.2%

The firm has a market cap of $3.97 billion, a P/E ratio of 24.82, a P/E/G ratio of 1.47 and a beta of 0.30. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The business has a 50-day moving average price of $61.12 and a 200-day moving average price of $63.74.

Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Institutional Trading of Haemonetics

A number of hedge funds have recently bought and sold shares of HAE. Parkside Financial Bank & Trust increased its holdings in shares of Haemonetics by 11.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 152 shares during the period. GAMMA Investing LLC raised its holdings in Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 165 shares in the last quarter. Quarry LP lifted its position in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 192 shares during the last quarter. Verdence Capital Advisors LLC boosted its holdings in shares of Haemonetics by 3.6% in the 2nd quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier’s stock valued at $464,000 after buying an additional 214 shares in the last quarter. Finally, Retirement Systems of Alabama grew its position in shares of Haemonetics by 0.4% in the 2nd quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock worth $4,581,000 after buying an additional 256 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Read More